| Code | 7114B | ||||||||||
| MA number | 21/0208/98-S | ||||||||||
| Product Form: | tbl mcp 14x5 mg (fľ.HDPE) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | GlaxoSmithKline Trading Services Limited, Ireland | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 8(3) application - new active substance |
| MA issued: | 28.04.1998 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Lamictal 5_100 mg_tbl mcp_07.2024.pdf
|
| SPC: |
SPC_Lamictal 5_100 mg_tbl mcp_07.2024.pdf
|
| Safety feature | Yes |
| Data update: | 29.05.2018 |
